冠状动脉搭桥术患者出现急性冠状动脉综合征的结果:血运重建的影响。

IF 2.6 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS
Hilary J Bews, Brett Hiebert, Shuangbo Liu, John Ducas, Amir Ravandi, Kunal Minhas, Malek Kass, Michael P Love, Harindra C Wijeysundera, Ashish H Shah
{"title":"冠状动脉搭桥术患者出现急性冠状动脉综合征的结果:血运重建的影响。","authors":"Hilary J Bews, Brett Hiebert, Shuangbo Liu, John Ducas, Amir Ravandi, Kunal Minhas, Malek Kass, Michael P Love, Harindra C Wijeysundera, Ashish H Shah","doi":"10.1177/17539447241308047","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients post-coronary artery bypass graft (CABG) can re-present with acute coronary syndrome (ACS); however, culprit lesion identification, as well as revascularization, is often challenging. Furthermore, the impact of revascularization in this patient group is relatively unknown.</p><p><strong>Objectives: </strong>The purpose of our study was to evaluate the efficacy of percutaneous coronary intervention (PCI) in patients with previous CABG surgery presenting with ACS.</p><p><strong>Methods: </strong>Using data from the Manitoba Center for Health Policy, we identified patients treated with CABG between April 1979 and March 2018, who subsequently presented with the primary diagnosis of ACS. Patients were divided into four groups: (1) managed medically and not investigated by cardiac catheterization and (2) investigated by cardiac catheterization and treated (2a) medically, (2b) with PCI, and (2c) with redo-CABG. Inverse probability treatment-weighted survival analyses were performed. Ethical approval was obtained from the local research board.</p><p><strong>Results: </strong>Nearly 20% of patients treated with CABG presented with ACS at a median of 7.2 years (age at the time of CABG: 66 years (interquartile range: 58-73 years); 75.6% male). Patients treated with PCI (<i>N</i> = 929) demonstrated improved survival compared to the patients investigated by catheterization but treated medically (<i>N</i> = 952; hazard ratio 0.87, 95% confidence interval 0.77-0.97, <i>p</i> = 0.02). Patients who underwent redo CABG (<i>N</i> = 171) experienced 13% mortality within the first year, but subsequently, demonstrated a trend toward improved survival.</p><p><strong>Conclusion: </strong>ACS is not uncommon following CABG. Revascularization is associated with prognostic improvement; however, such could be accounted for by inherent group differences, including comorbidities and coronary anatomy These findings should be validated in a prospective randomized study.</p>","PeriodicalId":23035,"journal":{"name":"Therapeutic Advances in Cardiovascular Disease","volume":"19 ","pages":"17539447241308047"},"PeriodicalIF":2.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696952/pdf/","citationCount":"0","resultStr":"{\"title\":\"Outcomes among patients with coronary artery bypass grafts presenting with acute coronary syndrome: impact of revascularization.\",\"authors\":\"Hilary J Bews, Brett Hiebert, Shuangbo Liu, John Ducas, Amir Ravandi, Kunal Minhas, Malek Kass, Michael P Love, Harindra C Wijeysundera, Ashish H Shah\",\"doi\":\"10.1177/17539447241308047\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Patients post-coronary artery bypass graft (CABG) can re-present with acute coronary syndrome (ACS); however, culprit lesion identification, as well as revascularization, is often challenging. Furthermore, the impact of revascularization in this patient group is relatively unknown.</p><p><strong>Objectives: </strong>The purpose of our study was to evaluate the efficacy of percutaneous coronary intervention (PCI) in patients with previous CABG surgery presenting with ACS.</p><p><strong>Methods: </strong>Using data from the Manitoba Center for Health Policy, we identified patients treated with CABG between April 1979 and March 2018, who subsequently presented with the primary diagnosis of ACS. Patients were divided into four groups: (1) managed medically and not investigated by cardiac catheterization and (2) investigated by cardiac catheterization and treated (2a) medically, (2b) with PCI, and (2c) with redo-CABG. Inverse probability treatment-weighted survival analyses were performed. Ethical approval was obtained from the local research board.</p><p><strong>Results: </strong>Nearly 20% of patients treated with CABG presented with ACS at a median of 7.2 years (age at the time of CABG: 66 years (interquartile range: 58-73 years); 75.6% male). Patients treated with PCI (<i>N</i> = 929) demonstrated improved survival compared to the patients investigated by catheterization but treated medically (<i>N</i> = 952; hazard ratio 0.87, 95% confidence interval 0.77-0.97, <i>p</i> = 0.02). Patients who underwent redo CABG (<i>N</i> = 171) experienced 13% mortality within the first year, but subsequently, demonstrated a trend toward improved survival.</p><p><strong>Conclusion: </strong>ACS is not uncommon following CABG. Revascularization is associated with prognostic improvement; however, such could be accounted for by inherent group differences, including comorbidities and coronary anatomy These findings should be validated in a prospective randomized study.</p>\",\"PeriodicalId\":23035,\"journal\":{\"name\":\"Therapeutic Advances in Cardiovascular Disease\",\"volume\":\"19 \",\"pages\":\"17539447241308047\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11696952/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Cardiovascular Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/17539447241308047\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Cardiovascular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/17539447241308047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:冠状动脉旁路移植术(CABG)后患者可再次出现急性冠脉综合征(ACS);然而,罪魁祸首病变的识别,以及血运重建,往往是具有挑战性的。此外,在这组患者中,血运重建的影响是相对未知的。目的:本研究的目的是评估经皮冠状动脉介入治疗(PCI)对既往冠脉搭桥患者ACS的疗效。方法:使用马尼托巴卫生政策中心的数据,我们确定了1979年4月至2018年3月期间接受冠脉搭桥治疗的患者,这些患者随后被初步诊断为ACS。患者分为四组:(1)医学治疗,不接受心导管检查;(2)心导管检查,接受治疗(2a)医学治疗,(2b) PCI治疗,(2c) redocabg治疗。进行反概率治疗加权生存分析。获得了当地研究委员会的伦理批准。结果:近20%接受CABG治疗的患者在中位7.2岁时出现ACS (CABG时年龄:66岁(四分位数范围:58-73岁);75.6%的男性)。接受PCI治疗的患者(N = 929)比接受导管治疗但接受药物治疗的患者(N = 952;风险比0.87,95%置信区间0.77 ~ 0.97,p = 0.02)。再次行CABG的患者(N = 171)在第一年的死亡率为13%,但随后表现出改善生存的趋势。结论:冠脉搭桥术后ACS并不少见。血运重建与预后改善有关;然而,这可以通过固有的组差异来解释,包括合并症和冠状动脉解剖。这些发现应该在前瞻性随机研究中得到验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Outcomes among patients with coronary artery bypass grafts presenting with acute coronary syndrome: impact of revascularization.

Background: Patients post-coronary artery bypass graft (CABG) can re-present with acute coronary syndrome (ACS); however, culprit lesion identification, as well as revascularization, is often challenging. Furthermore, the impact of revascularization in this patient group is relatively unknown.

Objectives: The purpose of our study was to evaluate the efficacy of percutaneous coronary intervention (PCI) in patients with previous CABG surgery presenting with ACS.

Methods: Using data from the Manitoba Center for Health Policy, we identified patients treated with CABG between April 1979 and March 2018, who subsequently presented with the primary diagnosis of ACS. Patients were divided into four groups: (1) managed medically and not investigated by cardiac catheterization and (2) investigated by cardiac catheterization and treated (2a) medically, (2b) with PCI, and (2c) with redo-CABG. Inverse probability treatment-weighted survival analyses were performed. Ethical approval was obtained from the local research board.

Results: Nearly 20% of patients treated with CABG presented with ACS at a median of 7.2 years (age at the time of CABG: 66 years (interquartile range: 58-73 years); 75.6% male). Patients treated with PCI (N = 929) demonstrated improved survival compared to the patients investigated by catheterization but treated medically (N = 952; hazard ratio 0.87, 95% confidence interval 0.77-0.97, p = 0.02). Patients who underwent redo CABG (N = 171) experienced 13% mortality within the first year, but subsequently, demonstrated a trend toward improved survival.

Conclusion: ACS is not uncommon following CABG. Revascularization is associated with prognostic improvement; however, such could be accounted for by inherent group differences, including comorbidities and coronary anatomy These findings should be validated in a prospective randomized study.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Therapeutic Advances in Cardiovascular Disease
Therapeutic Advances in Cardiovascular Disease CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
3.50
自引率
0.00%
发文量
11
审稿时长
9 weeks
期刊介绍: The journal is aimed at clinicians and researchers from the cardiovascular disease field and will be a forum for all views and reviews relating to this discipline.Topics covered will include: ·arteriosclerosis ·cardiomyopathies ·coronary artery disease ·diabetes ·heart failure ·hypertension ·metabolic syndrome ·obesity ·peripheral arterial disease ·stroke ·arrhythmias ·genetics
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信